The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked CRA to evaluate the policies that host governments of middle-income countries use to encourage investment in innovative activities and the implications for future innovation. CRA consultants looked at eight countries and concluded that there are six key lessons that appear to be critical for success. Read more in the article here:
Drug pricing rules and tariffs reshape transfer pricing for IP
In the article “Drug Pricing Rules and Tariffs Reshape Transfer Pricing for IP,” published in Bloomberg Tax, CRA’s Transfer Pricing experts Robin Hart and ...